The two most prominent GLP-1 injectable medications — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — are expensive. That’s not a small detail. For many people, cost is the primary factor in whether these medications are accessible at all.

Here’s a realistic look at what these drugs actually cost, what insurance typically does and doesn’t cover, and what the alternative pathways look like.

List prices and what they mean

The list price of Ozempic is approximately $935–$970 per month (one pen, depending on dose). Wegovy — semaglutide at the higher dose used specifically for weight loss — is approximately $1,350–$1,450 per month. Mounjaro runs about $1,000–$1,100 per month. Zepbound (tirzepatide for weight loss) is approximately $1,060 per month.

These are sticker prices. Very few people pay list price if they have insurance — and also sometimes even without insurance through savings programs.

What insurance typically covers

Here’s where the same drug splits into very different coverage scenarios depending on your diagnosis.

Ozempic and Mounjaro are approved for type 2 diabetes. If you have a type 2 diabetes diagnosis, insurance — including most Medicare Part D plans — is significantly more likely to cover them. Many people with diabetes pay $25–$150 per month with insurance through manufacturer savings cards or tier-based formularies.

Wegovy and Zepbound are approved specifically for chronic weight management (obesity, defined as BMI ≥ 30, or BMI ≥ 27 with a weight-related health condition). Insurance coverage for weight loss medications has historically been poor. As of 2024, only about half of large employer plans cover GLP-1s for weight loss, and Medicare explicitly does not cover weight loss drugs (a limitation from federal law, though legislation to change this has been proposed).

This creates a gap: some people get these drugs almost free through insurance for diabetes and pay over $1,000 per month for the same drug’s weight-loss version without it.

Manufacturer savings programs

Eli Lilly (Mounjaro/Zepbound) and Novo Nordisk (Ozempic/Wegovy) both offer savings cards that can significantly reduce out-of-pocket costs — sometimes to $25–$100 per month for commercially insured patients. These programs do not apply to Medicare or Medicaid patients.

Novo Nordisk’s patient assistance programs (NovoCare) offer free medication to qualifying patients meeting income thresholds. Eli Lilly has similar programs through Lilly Cares.

Compounded alternatives

During FDA-declared drug shortages in 2023 and 2024, compound pharmacies were legally permitted to produce semaglutide and tirzepatide versions. These compounded versions were sold through telehealth platforms at prices ranging from $150 to $400 per month — dramatically less than branded versions.

The FDA ended the semaglutide shortage designation in early 2025, which restricted compounding. Tirzepatide’s shortage status has been more variable. The legal and regulatory landscape around compounded GLP-1s continues to evolve; whether compounding is available at a given time depends on current FDA shortage designations.

The practical picture

For people with type 2 diabetes and commercial insurance, branded GLP-1s are often accessible at manageable cost through savings programs. For people seeking these drugs for weight loss without diabetes, the out-of-pocket math is significantly harder. Telehealth platforms offering compounded versions during shortage periods have provided a lower-cost pathway for some people, but availability and legal status are not stable.

If cost is a primary barrier, it’s worth calling your insurance company directly to ask about coverage, consulting a primary care physician about which diagnosis applies, and checking current shortage status with telehealth prescribers.


This content is for educational purposes only and is not medical advice. Consult your healthcare provider before making changes to your diet, supplements, or medications.